Pan-Cancer Analysis Revealed SRSF9 as a New Biomarker for Prognosis and Immunotherapy

Figure 5

The correlation between SRSF9 expression and pan-cancer immune subtypes and molecular subtypes using TISIDB: (a) in ACC, (b) in BRCA, (c) in COAD, (d) in KIRC, (e) in LGG, (f) in LUAD, (g) in LUSC, (h) in KIRP, (i) in PRAD, (j) in LIHC, and (k) in STAD. C1 (wound healing); C2 (IFN-gamma dominant); C3 (inflammatory); C4 (lymphocyte depleted); C5 (immunologically quiet); C6 (TGF-b dominant). The correlation between SRSF9 expression and pan-cancer molecular subtypes using TISIDB: (l) in ACC, (m) in LGG, (n) in LUSC, (o) in OV, and (p) in STAD.